Form 4: Orchestra BioMed CEO Awarded 200K RSUs

Orchestra BioMed Holdings, Inc. CEO David P. Hochman received an award of 200,000 restricted stock units, vesting over three years.

Summary

• David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc. (OBIO), was awarded 200,000 restricted stock units (RSUs) on August 7, 2025.
• Each RSU represents a contingent right to receive one share of Common Stock.
• 100,000 RSUs were awarded directly to Mr. Hochman, increasing his direct beneficial ownership to 645,460 shares.
• An additional 100,000 RSUs were awarded indirectly via the DPH 2008 Trust, increasing its beneficial ownership to 449,331 shares.
• The RSUs vest over a three-year period, contingent on Mr. Hochman's continuous service: 33.33% will vest 24 months after the grant date, 33.33% after 30 months, and 33.34% after 36 months.

Sentiment

Score: 7

Explanation: The RSU award is a positive signal of management's long-term commitment and aligns their interests with shareholders, which is generally viewed favorably. It's a standard compensation practice, not an extraordinary event, hence a moderate positive score.

Positives

• The award of 200,000 restricted stock units to the CEO aligns his interests with long-term shareholder value creation.
• The multi-year vesting schedule encourages continuous service and sustained performance from key management.

Negatives

• The RSU award does not provide immediate cash compensation, as its value is realized only upon vesting.
• The ultimate value of the award is contingent on the future stock price performance of Orchestra BioMed Holdings, Inc.

Future Outlook

The award of restricted stock units with a three-year vesting schedule indicates a long-term commitment to the company's future performance and aligns executive incentives with shareholder value creation over this period.

Industry Context

Executive equity compensation, particularly through restricted stock units, is a standard practice across various industries, including biotechnology and medical devices, to incentivize long-term performance and retain key leadership.

Comparison to Industry Standards

• The grant of 200,000 RSUs to a CEO of a company like Orchestra BioMed Holdings, Inc. is a common form of long-term incentive compensation in the biotechnology and medical device sectors.
• Vesting schedules over three years are typical for such awards, comparable to practices at companies like Medtronic or Boston Scientific for their executive compensation packages, aiming to ensure executive retention and alignment with multi-year strategic goals.
• The use of RSUs at a $0 price is standard for equity awards that are not options, reflecting a direct grant of future shares.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of CEO's interests with long-term stock performance.
• Employees: May signal stability in leadership and a commitment to long-term growth, potentially boosting morale.

Next Steps

• Vesting of 33.33% of RSUs on August 7, 2027.
• Vesting of 33.33% of RSUs on February 7, 2028.
• Vesting of 33.34% of RSUs on August 7, 2028.

Key Dates

Recommendation

This filing details a routine executive compensation event (RSU award) which, while positive for aligning management incentives, does not present new fundamental information that would significantly alter the investment thesis for Orchestra BioMed Holdings, Inc. It reinforces a 'hold' position as it's an expected part of ongoing corporate governance and executive retention strategies.

Keywords

Orchestra BioMed Holdings, OBIO, David P. Hochman, Restricted Stock Units, RSU, Executive Compensation, Insider Trading, SEC Form 4, Equity Award, Corporate Governance